Evidence map›Paper›PMID 35205614›Full record

ArticleCancers2022

hPG

Aman Chauhan, Alexandre Prieur, Jill Kolesar, Susanne Arnold, Léa Payen, Younes Mahi, Berengere Vire, Madison Sands, B Mark Evers, Dominique Joubert and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Plasma hPGBMC cancer · 2023
    Article
  3. Review
  4. Evaluation of hPGCancer diagnosis & prognosis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Aman ChauhanDivision of Medical Oncology, and the Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
Alexandre PrieurECS Progastrin, 1004 Lausanne, Switzerland.
Jill KolesarCollege of Pharmacy, and the Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.ORCID 0000-0003-1802-6439
Susanne ArnoldDivision of Medical Oncology, and the Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
Léa PayenLyon Sud Hospital, 69310 Pierre-Benite, France.
Younes MahiECS Progastrin, 1004 Lausanne, Switzerland.
Berengere VireECS Progastrin, 1004 Lausanne, Switzerland.
Madison SandsSchool of Medicine, University of Kentucky, Lexington, KY 40536, USA.ORCID 0000-0001-6234-6638
B Mark EversDepartment of Surgery, and the Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
Dominique JoubertECS Progastrin, 1004 Lausanne, Switzerland.
Lowell AnthonyDivision of Medical Oncology, and the Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.ORCID 0000-0001-7348-7874
University of Kentucky · USHôpital Lyon Sud · FR

Funding

UM1 Supplement for Early Therapeutic Trials with Phase 2 IntentUM1CA186712 · NCI · OHIO STATE UNIVERSITY · PI SUSANNE M ARNOLD, WILLIAM E. CARSON · 2014 to 2026
$19.3M
NCI NIH HHS UM1 CA186712
6 · The paper itself

Abstract

Current blood-based biomarkers for neuroendocrine neoplasms (NENs) lack both sensitivity and specificity. Human circulating progastrin (hPG

Indexed as

blood-based diagnostic biomarkercirculating progastrinhPG80neuroendocrine carcinomaneuroendocrine neoplasmsneuroendocrine tumorssmall-cell carcinoma

Identifiers

PMID35205614
PMCPMC8870162
OpenAlexW4211183159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.